rAAt (dermatological) Arriva/ProMetic

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 1, 2006, Pages 69-75

  Brown, William M ^a  

^a Paddock Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; AP 102; HYDROCORTISONE; ILOMASTAT; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; NONHUMAN; OTITIS MEDIA; PSORIASIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, TOPICAL; ALPHA 1-ANTITRYPSIN; CLINICAL TRIALS, PHASE II; DERMATITIS, ATOPIC; DRUG INDUSTRY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32544460409     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. 160297 Liver transplantation for end-stage liver disease associated with α-1-antirypsin deficiency in children: Pretransplant natural history, timing and results of transplantation. Filipponi F, Soubrane O, Labrousse F, Devictor D, Bernard O, Valayer J, Houssin D J HEPATOLOGY 1994 20 1 72-78
2. 1-proteinase inhibitor. Wachter AM, Lezdey J ANN ALLERGY 1992 69 5 407-414
3. 276351 AlphaOne pursues recombinant AAT drug. BIOWORLD WEEK 1998 6 5 2
4. 1-AT study group. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N EUR RESPIR J 1997 10 10 2260-2263
5. 323408 AlphaOne's emphysema drug may also offer hope for asthma sufferers. AlphaOne Pharmaceuticals Inc PRESS RELEASE 1999 May 03
6. 1-antitrypsin deficiency in children. Clinical, biological and respiratory function study in 132 cases. Sablayrolles B, Dutau G, Constans J, Labbe A, Rochiccioli P ARCH FR PEDIATR 1986 43 6 389-393
7. 1-Antitrypsin-deficiency: Memorandum from a WHO meeting. Anonymous BULL WORLD HEALTH ORGAN 1997 75 5 397-415
8. 353573 Elevated levels of human neutrophil peptides in the epithelial lining fluid of patients with cystic fibrosis. Spencer LT, Flotte TR, Brantly ML PEDIATRIC PULMONOLOGY 1999 19 Suppl 544
9. 1-antitrypsin. Baxter Healthcare Corp PRESS RELEASE 2000 March 20
10. 1-antitrypsin project. ProMetic Life Sciences Inc PRESS RELEASE 2000 March 21
11. 394981 AlphaOne renamed Arriva Pharmaceuticals. AlphaOne Pharmaceuticals Inc PRESS RELEASE 2001 January 03
12. 403510 Arriva/ProMetic skin Inflammation patent triumphs over opposition. ProMetic Life Sciences Inc, Arriva Pharmaceuticals Inc PRESS RELEASE 2001 March 29
13. 1-antitrypsin patent. Arriva Pharmaceuticals Inc PRESS RELEASE 2001 April 05
14. 406711 ProMetic completes equity stake in AlphaOne; ProMetic positioning for growth in therapeutics. ProMetic Life Sciences Inc PRESS RELEASE 2000 November 16
15. 452308 Arriva licenses ZymoGenetics's α-1-antitrypsin patent. ZymoGenetics Inc, Arriva Pharmaceuticals Inc PRESS RELEASE 2002 May 23
16. 465408 BioPartnering - ProMetic Life Sciences Inc. ANNU BIOPARTNERING EUROPE MEET 2002 10 October 13-15
17. 467373 Press preview: From protein purification to drug discovery. ProMetic Life Sciences Inc COMPANY PUBLICATION 2002 1 1-3
18. 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. Arriva Pharmaceuticals Inc PRESS RELEASE 2002 November 07
19. 480737 Baxter/Arriva's AAT moves into emphysema trials. Baxter Healthcare Corp PRESS RELEASE 2003 March 04
20. 491463 Baxter launches Aralast in US for hereditary emphysema. Baxter International Inc PRESS RELEASE 2003 May 30
21. 492344 Arriva's rAAT shows promise in otitis media. Arriva Pharmaceuticals Inc PRESS RELEASE 2003 June 04
22. 500102 Inflammation 2003 - Sixth World Congress (Part II) - OVERNIGHT REPORT, Vancouver, Canada. Evans R IDDB MEETING REPORT 2003 August 02-06
23. 1-antitrypsin (RHAAT) inhibits delayed-type hypersensitivity in an oxazolone-induced model in mice. Gagnon L, Asselin M, Gaundreau D, Sarra-Bournet F, Zacharie B, Barabe J, Laurin P, Penney C INFLAMM RES 2003 52 Suppl 2 10.8
24. 500810 Arriva/ProMetic's rAAT finishes phase I study. ProMetic Life Sciences Inc PRESS RELEASE 2003 August 13
25. 508298 Arriva-ProMetic begins phase II study of rAAT gel in dermatitis. Arriva Pharmaceuticals Inc PRESS RELEASE 2003 October 09
26. 524751 Clinical development and product pipeline. Arriva Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2004 February 26
27. 1-antitrypsin deficiency? Barr P SMI CONF - CHRON OBSTRUCT PULM DISORDERS 2004 March 10-11
28. 552363 Prometic reports on financial results for its second quarter 2004. ProMetic Life Sciences Inc PRESS RELEASE 2004 August 03
29. 1-Antitrypsin: More than just deficiency. Stockley RA THORAX 2004 59 5 363-364
30. 1-antitrypsin in skin diseases. Prometic Life Sciences Inc PRESS RELEASE 2004 October 07
31. 1-antitrypsin. ProMetic Life Sciences Inc COMPANY PUBLICATION 2004 October 31
32. 1- antitrypsin gene (PI) to 14q31-32. Schroeder WT, Miller MF, Woo SL, Saunders GF AM J HUM GENET 1985 37 5 868-872
33. 619840 The eletrophoretic α-1-globulin pattern of serum in α-1 antitrypsin deficiency. Laurell CB, Eriksson S SCAND J CLIN LAB INVEST 1963 15 132-140
34. 1-Antitrypsin. Hope on the horizon for emphysema sufferers? Schwaiblmair M, Vogelmeier C DRUGS AGING 1998 12 6 429-440
35. 1-antitrypsin deficiency. MacDonald JL, Johnson CE AM J HEALTH SYST PHARM 1995 52 5 481-489
36. 1-antitrypsin deficiency. Luisetti M, Seersholm N THORAX 2004 59 2 164-169
37. 1-antitrypsin deficiency allele Mmalton. Curiel DT, Holmes MD, Okayama H, Brantly ML, Vogelmeier C, Travis WD, Stier LE, Perks WH, Crystal RG J BIOL CHEM 1989 264 23 13938-13945
38. 619848 Molecular basis of α-1-antitrypsin deficiency. Brantly M, Nukiwa T, Crystal RG AM J MED 1988 84 6A 13-31
39. 1-Antitrypsin deficiency. Ellett ML GASTROENTEROL NURS 1991 14 3 138-141
40. 1-antitrypsin. Kang HA, Lee KN, Yu MH J BIOL CHEM 1997 272 1 510-516
41. 619851 Polymerized α-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of α-antitrypsin polymerization. Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S HISTOPATHOLOGY 2004 45 6 587-592
42. 1-antitrypsin-related emphysema. Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R AM J RESPIR CELL MOL BIOL 2004 31 2 133-139
43. 1-antitrypsin. Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA J BIOL CHEM 1999 274 14 9548-9555
44. 1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Mulgrew AT, Taggart CC, Lawless MW, Greens CM, Brantly ML, O'Neill SJ, McElvaney NG CHEST 2004 125 5 1952-1957
45. 1- antitrypsin mutants that are retained to the endoplasmic reticulum. Schmidt BZ, Perimutter DH AM J PHYSIOL GASTROINTEST LIVER PHYSIOL 2005 289 3 G444-G455
46. 1-antitrypsin deficiency. Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D AM J PHYSIOL GASTROINTEST LIVER PHYSIOL 2004 286 5 G851-G862
47. 1-Antitrypsin augmentation therapy. Pierce JA CHEST 1997 112 4 872-874
48. 1-antitrypsin deficiency. Juvelekian GS, Stoller JK DRUGS 2004 64 16 1743-1756
49. 1-Antitrypsin deficiency. 5: Intravenous augmentation therapy: Current understanding. Stoller JK, Aboussouan LS THORAX 2004 59 8 708-712
50. 1-antitrypsin. The α-1-Antitrypsin Deficiency Registry Study Group AM J RESPIR CRIT CARE MED 1998 158 1 49-59
51. 1-AT-study group. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N EUR RESPIR J 1998 11 428-433
52. 1-antitrypsin deficiency. Stockley RA, Bayley DL, Unsal I, Dowson LJ AM J RESPIR CRIT CARE MED 2002 165 11 1494-1498
53. 1-antitrypsin, Respitin. Stoller JK, Rouhani F, Brantly M, Shahin S, Dweik RA, Stocks JM, Clausen J, Campbell E, Norton F CHEST 2002 122 1 66-74
54. 1-antitrypsin and polymorphonuclear leukocyte elastase contents and their immunogenetic correlation in psoriasis. Nini G, Bianchi L, Angelini E, Corleto V, Gatti S, Carrozzo AM ACTA DERM VENEREOL SUPPL (STOCKH) 1994 186 143-145
55. 1-Proteinase inhibitor in psoriasis: Reduced activity in symptom-free patients and during flare. Barszcz D, Zarebska Z, Glinska-Ferenz M, Jablonska S, Tigalonowa M, Glinski W ARCH DERMATOL RES 1988 280 4 198-206
56. 1-antitrypsin deficiency. Heng MC, Kloss SG J INVEST DERMATOL 1986 87 1 59-64
57. 1-Antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions. Antonelli PJ, Schultz GS, Kim KM, Cantwell JS, Sundin DJ, Pemberton PA, Barr PJ LARYNGOSCOPE 2003 113 8 1347-1351
58. 620705 Inflammatory proteases in chronic otitis externa. Antonelli PJ, Schultz GS, Cantwell JS, Sundin DJ, Pemberton PA, Barr PJ LARYNGOSCOPE 2005 115 4 651-654
59. 620974 Production of serpins using yeast expression systems. Pemberton PA, Bird PI METHODS 2004 32 2 185-190
60. 1-antitrypsin by the native strain distributed throughout the molecule. Seo EJ, Lee C, Yu MH. J BIOL CHEM 2002 277 16 14216-14220
61. 1-antitrypsin. Bottomley SP, Lawrenson ID, Tew D, Dal W, Whisstock JC, Pike RN PROTEIN SCI 2001 10 12 2518-2524
62. 1-antitrypsin. Im H, Seo EJ, Yu MH J BIOL CHEM 1999 274 16 11072-11077
63. 1-antitrypsin. James EL, Whisstock JC, Gore MG, Bottomley SP J BIOL CHEM 1999 274 14 9482-9488
64. 621046 The P6-P2 region of serpins is critical for proteinase inhibition and complex stability. Chaillan-Huntington CE, Gettins PG, Huntington JA, Patston PA BIOCHEMISTRY 1997 36 31 9562-9570
65. 1-antitrypsin to its reaction with elastase. Hopkins PC, Stone SR BIOCHEMISTRY 1995 34 48 15872-15879
66. 1-antitrypsin is in the canonical inhibitory conformation. Elliott PR, Abraham JP, Lomas DA J MOL BIOL 1998 275 3 419-425
67. 1-antitrypsin reveals the conformation of its inhibitory reactive loop. Song HK, Lee KN, Kwon KS, Yu MH, Suh SW FEBS LETT 1995 377 2 150-154
68. 1-proteinase inhibitor blocks antigen- and mediator-induced airway responses in sheep. Scuri M, Botvinnikova Y, Lauredo IT, Abraham WM J APPL PHYSIOL 2002 93 6 1900-1906
69. 626309 Now insights into atopic dermatitis. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA J CLIN INVEST 2004 113 5 651-657
70. 1-antitrypsin and ilomastat in human otitis media. Antonelli PJ, Schultz GS, Kim KM, Cantwell JS, Sundin DJ, Pemberton PA, Barr PJ INT SYMP REC ADV OTITIS MEDIA 2003 6 June 08
71. 1-antitrypsin does not prevent its synthesis and secretion. Foreman RC FEBS LETT 1987 216 1 79-82
72. 1-antitrypsin deficiency - a model for conformational diseases. Carrell RW, Lomas DA N ENG J MED 2002 346 1 45-53
73. 638185 Cell toxicity and conformational disease. Carrell RW TRENDS CELL BIOL 2005 15 11 574-580
74. 646113 Recombinant protein expression and purification. Arriva Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2006 January 19